{"id":8672,"date":"2018-02-07T14:57:44","date_gmt":"2018-02-07T21:57:44","guid":{"rendered":"http:\/\/canadianglycomics.ca\/?p=8672"},"modified":"2019-08-01T11:02:37","modified_gmt":"2019-08-01T17:02:37","slug":"glyconet-partners-fund-3-5-million-in-health-research","status":"publish","type":"post","link":"https:\/\/canadianglycomics.ca\/fr\/glyconet-partners-fund-3-5-million-in-health-research\/","title":{"rendered":"GlycoNet, partners fund $3.5 million in health research"},"content":{"rendered":"

Grants awarded to 36 researchers across 18 institutions Canada-wide <\/em>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/h3>\n

EDMONTON (February 7, 2018) \u2013 The R\u00e9seau Canadien de la Glycomique<\/a> (GlycoNet) along with partner institutions recently awarded more than $3.5 million in grants to fund exploratory research in the area of glycomics to benefit human health.<\/p>\n

The funds are distributed to more than 36 researchers at 18 institutions across Canada.<\/p>\n

The grants will fund research to benefit human health, such as improved imaging of a key enzyme in Parkinson\u2019s disease, understanding why Alzheimer\u2019s-causing plaques form in the brain, developing an oral medication to fight drug-resistant fungi, and assessing a plant-based therapy to treat and prevent kidney stones.<\/p>\n

\u201cWe are pleased to fund this latest round of research proposals and are confident our innovative and entrepreneurial culture will help this research impact the health and well-being of Canadians in years to come,\u201d says GlycoNet Scientific Director, Dr. Todd Lowary. \u201cWe continue to build critical mass in our research areas and count more than 114 researchers in our network who are the top in their field.\u201d<\/p>\n

GlycoNet is a national research network based at the University of Alberta. GlycoNet focuses on the study of glycomics, the non-food roles of carbohydrates in biological systems, particularly in relation to five themes: antimicrobials, rare genetic diseases, diabetes and obesity, chronic disease and therapeutic proteins and vaccines. Catalyst and Translational grants are funded for one year while Collaborative Team grants, where research partners match Networks of Centres of Excellence funding, are funded for two years.<\/p>\n

In addition to funding, GlycoNet will provide technical support for the projects, including access to core services required to undertake the work, resources related to business development and protection of intellectual property and assistance developing collaborations with industry.<\/p>\n

GlycoNet invited applications for multidisciplinary research projects designed to fit within the network\u2019s five research themes. After an extensive review process, GlycoNet awarded the following 14 projects, listed below. More details, including project summaries, are available at http:\/\/canadianglycomics.ca\/projects\/<\/a><\/p>\n

ANTIMICROBIENS<\/u><\/strong><\/span><\/p>\n

Inhibiting glycosylphosphatidylinositol (GPI) anchor biosynthesis to treat drug-resistant fungal infections.
\n<\/strong>Dr. Leah Cowen (University of Toronto)
\nTotal project value<\/strong>: $200,000<\/p>\n

CHRONIC DISEASES<\/u><\/strong><\/span><\/p>\n

Carbohydrate antigens-functionalized silver nanoparticles \u2013Toward a fast and sensitive assay for clinical diagnostic of prostate cancer.<\/strong>
\nDr. Denis Gigu\u00e8re (University of Laval)
\nTotal project value<\/strong>: $75,000<\/p>\n

Development of antibodies targeting 9-O-acetyl-GD2 for cancer treatment and diagnosis.<\/strong>
\nDr. Kenneth Ng (University of Calgary); Dr. Chang-Chun Ling (University of Calgary); Dr. Jamshid Tanha (National Research Council)
\nTotal project value<\/strong>: $72,000<\/p>\n

A mass spectrometry-based approach to elucidate the glycan ligands of CD33 implicated in Alzheimer’s disease.<\/strong>
\nDr. Matthew Macauley (University of Alberta); Dr. John Klassen (University of Alberta)
\nTotal project value<\/strong>: $75,000<\/p>\n

Atypical glycan based liquid biopsy for risk stratification in early breast cancer.
\n<\/strong>Dr. Karla Williams (University of British Columbia); Dr. Peter Watson (University of British Columbia)
\nTotal project value<\/strong>: $701,056\u00a0<\/strong><\/p>\n

Evaluation of PET radiotracers for imaging glucocerebrosidase in Parkinson’s disease.<\/strong>
\nDr. Christopher Phenix (University of Saskatchewan); Dr. Rebecca Davis (University of Manitoba); \u00a0Dr. Justin Hicks (Lawson Health Research Institute); Dr. Darrell Mousseau (University of Saskatchewan); Dr. David Palmer (University of Saskatchewan)
\nTotal project value<\/strong>: $554,456<\/p>\n

Development and validation of a quantitative clinical flow cytometry assay for selective measurement of GCase activity in peripheral blood mononuclear cells.
\n<\/strong>Dr. David Vocadlo (Simon Fraser University); Dr. Jon Stoessl (University of British Columbia); Dr. Vesna Sossi (University of British Columbia); Dr. Ziv Gan-Or (McGill University); Dr. Edward Fon (McGill University); Dr. Thomas Duncan (McGill University)
\nTotal project value<\/strong>: $488,693<\/p>\n

Cardioprotective nucleoside analogues for chemotherapy
\n<\/strong>Dr. Yvan Guindon (Institut de recherches cliniques de Montr\u00e9al); Dr. Mona Nemer (University of Ottawa)
\nTotal project value<\/strong>: $131,711<\/p>\n

DIABETES & OBESITY<\/u><\/strong><\/span><\/p>\n

Towards gut microbiota modulation using dietary glycans.<\/strong>
\nDr. Bastien Castagner (McGill University); Dr. Corrine Maurice (McGill University)
\nTotal project value<\/strong>: $75,000<\/p>\n

MALADIES G\u00c9N\u00c9TIQUES RARES<\/u><\/strong><\/span><\/p>\n

Preparatory studies for phase I\/II clinical trial to correct GM2 gangliosidosis using AAV9 based gene therapy.
\n<\/strong>Dr. Jagdeep Walia (Queens University); Dr. Brian Lichty (McMaster University)
\nTotal project value<\/strong>: $196,780<\/p>\n

Engineering human hexosaminidase for gene and enzyme replacement therapies.
\n<\/strong>Dr. Brian Mark (University of Manitoba); Dr. Helene Perreault (University of Manitoba); Dr. Barbara Triggs-Raine (University of Manitoba)
\nTotal project value<\/strong>: $74,950<\/p>\n

PROT\u00c9INES ET VACCINS TH\u00c9RAPEUTIQUES<\/u><\/strong><\/span><\/p>\n

Attenuating antibody fucosylation with carbafucose analogues.
\n<\/strong>Dr. Robert Britton (Simon Fraser University); Dr. David Vocadlo (Simon Fraser University)
\nTotal project value<\/strong>: $75,000<\/p>\n

Investigation of glycosylated pilins as a new TB vaccine for respiratory mucosal immunization.<\/strong>
\nDr. Lori Burrows (McMaster University)
\nTotal project value<\/strong>: $246,330<\/p>\n

Glycan remodelling of plant derived therapeutic proteins.<\/strong>
\nDr. Warren Wakarchuk (Ryerson University); Dr. Alasdair Boraston (University of Victoria)
\nTotal project value<\/strong>: $449,200<\/p>\n

Clinical assessment of arbutin for the treatment and prevention of calcium oxalate kidney stones.<\/strong>
\nDr. Nicholas Power (Western University); Dr. Paul Spagnuolo (University of Guelph); Dr. Blayne Welk (Western University)
\nTotal project value<\/strong>: $90,200<\/p>","protected":false},"excerpt":{"rendered":"

Grants awarded to 36 researchers across 18 institutions Canada-wide <\/p>","protected":false},"author":2,"featured_media":10612,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[200],"tags":[],"class_list":["post-8672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","wpbf-post"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t